Clinical Trial Update: A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass [Phase 2]

View source ↗

Summary

Phase 2 trial of INO-1001 in patients undergoing heart surgery involving cardiopulmonary bypass has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Disease

Drugs mentioned

• INO-1001 (PARP inhibitor)

Snippet

Sponsor: Inotek Pharmaceuticals Corporation | Conditions: Heart Diseases, Postoperative Complications | Phase 2 | Status: TERMINATED